/ /

Vanessa Caceres
What's the best non-surgical treatment for exotropia?
Observation, patching, and the use of overminus lenses are three treatment approaches for intermittent exotropia; observation appears reasonable based on current research.
A tearscope made of paper?
A relatively simple device can help evaluate the lipid layer in tear film-related disease, according to researchers.
In-office MGD treatments may provide relief but lack formal studies
Surgeons have several in-office treatments available for meibomian gland dysfunction, but there are not many studies to show the long-term effectiveness.
Gel stent for glaucoma patients finds 40% reduction in IOP
Implantation of a gel stent for glaucoma studied in Europe led to a 40% reduction in IOP.
Consider PDGF treatment prior to anti-VEGF therapy
Patients with age-related macular degeneration patients who had received anti-platelet derived growth factor (PDGF) therapy prior to anti-VEGF treatment fared better than those who did not in a pilot study.
Signal strength important factor when analyzing OCT scans
Optical coherence tomography scans can be useful to follow glaucoma, but clinicians should be aware of scan quality.
Atropine explored as treatment for childhood myopia
Atropine slowed childhood myopia progression by 50% to 60% in two large trials in Asia.
Innovations fuel sustained drug-delivery methods for AMD
Innovations fuel sustained drug-delivery methods for AMD
A variety of newer drug delivery approaches may change how patients with age-related macular degeneration are treated.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progression
Treatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
Dr. David Apple's legacy endures through laboratory
Were he alive today, he would likely feel heartened by how his work has been carried on by Gerd U. Auffarth, MD, FEBO, who is now director of The David J Apple International Laboratory for Ocular Pathology at the University of Heidelberg, Germany.